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Abstract 
Background 
Many randomised trials assessing interferon-α (IFN-α) as adjuvant therapy for high-risk 
malignant melanoma have been undertaken. To better assess the role of IFN-α, an 
individual patient data (IPD) meta-analysis of these trials was undertaken. 
Methods 
IPD was sought from all randomised trials of adjuvant IFN-α versus no IFN-α for high-risk 
melanoma. Primary outcomes were event-free survival (EFS) and overall survival (OS). 
Standard methods for quantitative IPD meta-analysis were used. Subgroup analyses by 
dose, duration of treatment, and various patient and disease-specific parameters were 
performed. 
Findings 
Fifteen trials were included in the analysis (eleven with IPD). EFS was significantly 
improved with IFN-α (Hazard Ratio (HR)=0·86, CI 0·81-0·91; P<0·00001), as was OS 
(HR=0·90, CI 0·85-0·97; P=0·003). The absolute differences in EFS at five and ten years 
were 3·5% and 2·7%, and for OS were 3·0% and 2·8% respectively in favour of IFN-α. 
There was no evidence that the benefit of IFN-α differed depending on dose or duration of 
treatment, or by age, gender, site of primary tumour, disease stage, Breslow thickness, or 
presence of clinical nodes. Only for ulceration was there evidence of an interaction (test for 
heterogeneity: P=0·04 for EFS; P=0·002 for OS); only patients with ulcerated tumours 
appeared to obtain benefit from IFN-α. 
Conclusion 
This meta-analysis provides clear evidence that adjuvant IFN-α significantly reduces the 
risk of relapse and improves survival, and shows no benefit for higher doses. The 
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increased benefit in patients with ulcerated tumours, and lack of benefit in patients without 
ulceration, needs further investigation. 
 
Key Words: Individual patient data meta-analysis; randomised controlled trials; 
melanoma; adjuvant interferon. 
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Introduction 
Effective adjuvant therapy for melanoma remains an unmet need. Despite the approval of 
two new agents (Ipilimumab, PEGylated interferon (PEG-IFN)), the last five years have not 
seen improvements in overall survival (OS) in any adjuvant therapy study. Interferon 
remains a standard of care in many countries without a consensus view on its clinical utility. 
Results from randomised trials of adjuvant interferon-α (IFN-α) in high-risk melanoma have 
been considered inconsistent, with some suggesting benefit with IFN-α and others 
showing no difference.[1] In 1996, high dose IFN-α was approved in both the US and 
Europe based on the results of the ECOG 1684 trial in stage IIB/III patients, which showed 
a benefit for high dose IFN-α on both relapse-free survival (RFS) and OS.[2] Updated 
results with a median follow-up of 12·6 years, showed that the RFS benefit was 
maintained (Hazard Ratio (HR)=0·72, p=0·02), but the HR for OS had decreased from 
0·67 to 0·82 (p=0·18), possibly due to competing causes of death.[3] The ECOG E1690 
trial which compared high and low dose IFN-α versus observation also in stage IIB/III 
patients, had a very similar outcome for RFS for high and low dose, but did not confirm the 
benefit for high or low dose on OS.[4] 
 
In Europe, low dose IFN-α was also approved based on a French trial in stage II patients, 
which showed a RFS benefit (HR=0·75, p=0·035), and a trend towards improved OS 
(HR=0·72, p=0·059).[5] In 2011, the US Food and Drug Administration (FDA) approved 
PEG-IFN for stage III melanoma based on the EORTC 18991 trial, which showed an 
event-free survival (EFS) benefit (HR=0·82, p=0·01), but again no OS benefit.[6] 
 
Previous meta-analyses of the interferon trials have shown that IFN-α has a consistent 
effect on RFS, but no clear effect on OS.[7-9] No relationship with dose or duration of 
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treatment with outcome has been demonstrated.[7,8] IFN-α can have substantial side-
effects, especially at high doses. Obtaining a reliable estimate of the true benefit of IFN-α, 
and determining whether the magnitude of the benefit differs in different treatment 
regimens or disease characteristics is important. To this end, we have performed an 
individual patient data (IPD) meta-analysis of randomised trials of IFN-α versus no IFN-α in 
patients with high-risk melanoma. 
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Methods 
Trial Identification 
Randomised trials comparing IFN-α with no IFN-α in the adjuvant setting for the treatment 
of high-risk melanoma were identified by searches of registers and electronic databases 
including the Cochrane Controlled Trials Register, MEDLINE, EMBASE, PubMed, and 
Web of Science. This was supplemented by searching abstract books of conference 
proceedings from the main meetings (e.g. American Society of Clinical Oncology, World 
Melanoma Congress, ESMO/ECCO), scanning reference lists of retrieved papers, and 
contact with individual trialists. Trials of IFN-α versus other agents or involving vaccines 
were not considered for the primary analysis. 
 
Data Collection 
IPD was requested from all trials eligible for inclusion in the meta-analysis. For each 
patient, information was sought on age, gender, site of primary tumour, disease stage 
(American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma 
preferred [10]), Breslow thickness, ulceration, clinical nodes, and metastatic status. Data 
on allocated treatment, date of randomisation, date and site of first recurrence, date of first 
distant recurrence, and date and cause of death was also collected. All data were checked 
for internal consistency, and were amended or updated as necessary through 
correspondence with the responsible investigators. 
 
Statistical Analysis 
Standard meta-analytic methods were used to estimate an overall treatment effect for 
IFN-α versus no IFN-α (control) patients.[11-13] All analyses were based on the intention-
to-treat principle. To summarise, the number of events observed (O) in the IFN-α group of 
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each trial was compared with the number of events that would have been expected (E) if 
there was no difference between the IFN-α and control groups. The difference between 
these numbers, the observed minus expected (O-E), and its variance, yields the log-rank 
test for each trial. For trials providing IPD, each trial was analysed separately, and the log-
rank statistics were used to calculate that trial’s O-E and variance.[12] For trials where IPD 
was not provided, log-rank data was extracted from the publications, and the O-E and 
variance calculated using the methods described by Parmar.[13] From this O-E and 
variance, the HR and 99% confidence interval (CI) for each trial was calculated. Summing 
the statistics for each trial provides the overall statistics, which are presented as HR with 
95% CI.[12,13] 
 
For three-arm trials, treatment effects were estimated separately for each dose or duration 
of IFN-α versus control, but the control groups contribute only once to the totals (and 
relevant subtotals), with the statistics in the totals (and subtotals) being based on a single 
comparison of IFN-α (at either dose or duration) with no IFN-α. 
 
The results are presented as forest plots and survival curves. In the former, the HR and 
99% CI for each trial is represented graphically as a box with a line through it. The trials 
with IPD are shown as black boxes, and those trials with published data only are shown as 
white boxes. The overall results (and subtotals) are represented by diamonds, with the 
centre of the diamond giving the HR for the overall treatment effect and the width of the 
diamond the 95% CI. Only trials providing IPD contribute to the survival curves and 
subgroup analyses. 
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Outcome Measures 
The primary outcomes were EFS (time from randomisation to first event, either recurrence 
or death without recurrence) and OS (time from randomisation to death). Secondary 
outcomes were time to disease recurrence (or recurrence-free survival), time to first distant 
recurrence, and time to death without recurrence. 
 
These outcomes were analysed for all trials for which data were available. In the primary 
analysis, trials were divided by dose of IFN-α: high (20MU/m2), intermediate (5 or 10MU), 
low (3MU), and very low dose (1MU). The EORTC 18991 trial of PEG-IFN was placed in 
its own subgroup beneath the high dose trials on the forest plots, as although this trial was 
thought to provide a similar IFN dose to that of the high dose trials, PEG-IFN may have 
different properties to standard IFN-α. Differences in treatment effects between trials and 
subgroups of trials were assessed using tests of heterogeneity or tests for trend. For the 
primary analysis by IFN-α dose, the tests for trend excluded the EORTC 18991 study. 
 
Analyses were also performed with trials divided by duration of treatment (≤6, 12-18 and 
≥24 months) and by total scheduled dose (<250MU, 500-1000MU, 1300-3400MU and 
≥3500MU). For trials that provided IPD, the effect of IFN-α was also investigated by patient 
age (<40, 40-49, 50-59 and ≥60 years) and gender, and by different disease 
characteristics (site of primary tumour (limb or not limb), disease stage (stage I/II or stage 
III/IV as per definition used in each trial), Breslow thickness (≤1mm, 1.01-2.5mm, 2.51-
4mm or >4mm), ulceration (no, yes or unknown), and clinical node (node negative (N-), 
node positive (N+)). When interpreting the results of these subgroup analyses, emphasis 
should be placed on the relevant tests for heterogeneity between subgroups (or test for 
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trend if the subgroup levels are ordinal, e.g. age), and not on the p-values for each stratum 
within the subgroup. 
 
This IPD meta-analysis adheres to the guidelines provided by the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses of individual participant data.[14] 
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Results 
Fifteen randomised trials of IFN-α versus no IFN-α (control) were identified (Table 1, 
Supplemental Material Figure 1 and Supplemental Material Table 1).[2,4-6,15-24] There 
were three 3-arm studies comparing different doses or schedules of IFN-α with control, 
meaning there was 18 comparisons included in the analysis; ECOG 1690 trial [4] 
contributes to both the high and low dose IFN-α versus control subgroups, and the EORTC 
18952 [15] and Nordic [18] trials each contribute two separate comparisons within the 
intermediate dose group. IPD was provided for 11 of the 15 trials (Supplemental Material 
Table 2); summary data was used for the Nordic, Austrian MMCG, French CGM and 
Sunbelt trials. 
 
The 15 trials randomised 7744 patients (7699 patients analysed); the 11 trials providing 
IPD accounting for 5861 (76%) randomised patients. The mean age was 49 years (range: 
14 to 85), 57% were male, 61% were in disease stage III, mean Breslow thickness was 
3.8mm, 41% were clinical node positive, and 25% had ulcerated tumours (from 11 trials 
providing IPD; Supplemental Material Table 3). The duration of follow-up ranged from a 
mean of 3·4 years in the Austrian study (published data) to a median of 16·9 years in 
ECOG 1684 (IPD). 
 
Event-free survival 
Data on EFS were available for 7697 patients, with 4739 events reported. A significant 
improvement in EFS was seen with IFN-α compared with no IFN-α (HR=0·86, CI 0·81-
0·91; P<0·00001) (Figure 1). In the 11 trials providing IPD, the estimated HR was 0·88 (CI 
0·83-0·94; P=0·0003). This translated into absolute increases in five and ten year EFS of 
3·5% and 2·7% respectively in favour of IFN-α (Figure 2). There was no evidence of any 
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trend depending on the dose: high (0·83, 0·72-0·96); intermediate (0·84, 0·74-0·95); low 
(0·85, 0·77-0·94), and very low dose (0·99, 0·80-1·23) (test for trend: P=0·3) (Figure 1). 
There was also no evidence of any trend depending on the duration of treatment (P=0·7) 
(Supplemental Material Figure 2) or total planned dose (P=0·6) (Supplemental Material 
Figure 3). 
 
Overall Survival 
Survival data were available for all patients (n=7699), with 3899 deaths observed. There 
was a significant improvement in OS with IFN-α compared with no IFN-α (HR=0·90, CI 
0·85-0·97; P=0·003) (Figure 3). In the 11 trials providing IPD, the estimated HR was 0·91 
(CI 0·85-0·98, P=0·01). This translated into absolute increases in five and ten year OS of 
3·0% and 2·8% respectively in favour of IFN-α (Figure 4). There was no evidence of any 
trend depending on the dose: high (0·93, 0·80-1·08); intermediate (0·91, 0·79-1·04); low 
(0·86, 0·77-0·96), and very low dose (0·96, 0·76-1·21) (P=0·7) (Figure 3); duration of 
treatment (P=0·9) (Supplemental Material Figure 4); or total planned dose (P=0·4) 
(Supplemental Material Figure 5). 
 
Recurrence-free survival 
Recurrence-free survival was only available for the 11 trials providing IPD, with 3706 
recurrences among 5826 patients. The result was similar to that for EFS. There was a 
significant improvement in recurrence-free survival with IFN-α (HR=0·88, CI 0·83-0·95; 
P=0·0004), with no difference in the effect of IFN-α between the four dose groups (P=0·1). 
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Distant Recurrence 
Data on distant recurrence was only provided for 5 trials (WHO-16, DKG 80-1 and EORTC 
18952, 18871 and 18991). There was no difference in the risk of distant recurrence 
between IFN-α and no IFN-α (HR=0·94, CI 0·85-1·03; P=0·2), with no difference in the 
effect of IFN-α between doses (P=0·3) (Supplemental Material Figure 6). 
 
Death without Recurrence 
Death without recurrence was only available for the 11 trials providing IPD. There were 
few cases of patients dying before disease recurrence (138 in 5826 patients), with no 
evidence of a difference between treatment groups (HR=0·87, CI 0·62-1·23; P=0·4). There 
was no difference in the effect of IFN-α between the four dose groups (P=0·09). 
 
Subgroup Analyses by Patient and Disease Characteristics 
There was no clear evidence that the effect of IFN-α differed for either EFS or OS for most 
of the pre-specified subgroups (Figure 5, Supplemental Material Figure 7). Only for 
ulceration was there evidence of a difference. In patients with ulcerated tumours, a 
significant improvement in EFS was seen with IFN-α versus control (HR=0·79, CI 0·66-
0·94), compared to no difference in EFS in those with non-ulcerated tumours (HR=0·95, CI 
0·82-1·10) (test for interaction: P=0·04) (Figure 5). A similar result was observed for OS; 
with improved survival for IFN-α versus control for patients with ulcerated tumours 
(HR=0·77, CI 0·64-0·92), but no difference in survival for patients with non-ulcerated 
tumours (HR=1·02, CI 0·87-1·20) (test for interaction: P=0·002) (Supplemental Material 
Figure 7). For ulcerated melanoma, the absolute difference at ten years in EFS and OS 
was 6·9% and 10.5% respectively in favour of IFN-α (Supplemental Material Figure 8). 
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Vaccine Trials (ECOG 1694 and 2696) 
The primary analysis was an un-confounded comparison of IFN-α versus no IFN-α. There 
are also two vaccine trials: ECOG 1694 [25] comparing high dose IFN-α with GMK vaccine, 
and ECOG 2696 [26] (three-arm) comparing GM2-KLH/QS-21 vaccine with high dose IFN-
α started either immediately (on day 0) or delayed (start on day 14) with GM2-KLH/QS-21 
vaccine alone (Table 1, Supplemental Table 1). An analysis including the IPD from these 
trials gave the same results as the primary analysis (EFS: HR=0·86, CI 0·81-0·90; OS: 
HR=0·90, CI 0·85-0·96). 
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Discussion 
This IPD meta-analysis brings together all the currently available data from randomised 
trials of adjuvant IFN-α versus no IFN-α for the treatment of high-risk malignant melanoma, 
providing the most reliable assessment to date on the role of IFN-α. 
 
We have showed that IFN-α produces a clear benefit in terms of reducing the risk of 
recurrence, with a smaller benefit on OS. There was a highly significant 14% proportional 
reduction in the risk of an event (recurrence or death without recurrence) with IFN-α, 
similar to the 17% reduction observed in the published data meta-analysis of some of 
these trials reported previously.[7] In our published data meta-analysis, no significant 
benefit in OS was seen (7·3% reduction, P=0·1).[7] However, in this IPD meta-analysis, 
we found a significant 10% proportional reduction in the risk of death with IFN-α. Such a 
reduction might be clinically meaningful, although the absolute difference in mortality at 10 
years was small (approximately 3%). 
 
By collecting IPD, we were also able to assess the effect of IFN-α on recurrence-free 
survival, distant recurrence and death without recurrence. Data on distant recurrence was 
limited, though the effect size was consistent with that for EFS and recurrence-free 
survival. There were very few deaths without recurrence, with no difference between IFN-α 
and control. 
 
The analyses presented here provide no evidence of a dose response relationship with the 
results for both EFS and OS being similar across the four doses of IFN-α (high, 
intermediate, low and very low). There was also no evidence that the results differed by 
 15 
duration of treatment or total scheduled dose of IFN-α. This is an important finding, as high 
dose IFN-α is associated with significant toxicity and cost.  
 
One of the main benefits of undertaking an IPD meta-analysis is that it allows the 
investigation of whether the treatment effect differs in different types of patients. We found 
no evidence to suggest that the effect of IFN-α differed with age, gender, site of primary 
tumour, Breslow thickness, disease stage, or presence of clinical nodes. Only for 
ulceration was there evidence of a difference, with those patients with an ulcerated tumour 
treated with IFN-α having greater benefits in both EFS and OS than patients with non-
ulcerated tumours. 
 
The ulceration finding was first reported in an earlier iteration of this IPD meta-analysis.8 
Wheatley et al. reported that patients with ulcerated tumours had greater benefit from IFN-
α (EFS: HR=0·76, OS: HR=0·77) than those with no ulceration (EFS: HR=0·94, OS: 
HR=0·98).[8] In this updated analysis, the effect sizes are similar to those reported 
previously, but there is stronger evidence of a difference in benefit with IFN-α for ulcerated 
versus non-ulcerated tumours for OS. In an analysis of the two adjuvant EORTC IFN/PEG-
IFN trials, tumour load in the lymph nodes and ulceration of the primary tumour came out 
to be independent predictive factors for adjuvant IFN-α therapy.[27] However, these two 
EORTC trials were included in the meta-analysis, so this analysis does not provide 
independent validation. While we cannot yet prove that IFN only works in patients with 
ulcerated primary tumours, the possibility of a larger, and hence more clinically worthwhile, 
benefit in these patients – with a corresponding lack of benefit in non-ulcerated patients – 
could allow more efficient targeting of this agent to patients who may benefit, while 
avoiding it – along with the associated toxicity – in patients unlikely to benefit. 
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 Recently major advances in patients with advanced disease have been obtained with 
checkpoint inhibitors and with BRAF and MEK inhibitors.[28] Many of these agents are 
now being evaluated in the adjuvant setting. The control arm in these studies include 
placebo, high dose IFN and ipilimumab, highlighting the continuing lack of consensus 
agreement on what constitutes standard of care in the adjuvant setting. Adjuvant therapy 
with ipilimumab was approved by the FDA in 2015 on the basis of the results of the 
EORTC 18071 trial in stage III patients with high-risk for relapse, showing a significant 
improvement on event-free survival.[29] 
 
The limitations of this review include publication bias, a potential problem for any meta-
analysis. We had IPD for 11 of the 15 trials included in the meta-analysis; for the 
remaining four trials, published data was included. In these four trials, a slightly larger 
benefit for IFN-α was observed (EFS: HR=0·77, OS: HR=0·87). However, since IPD made 
up 76% of the data in this meta-analysis, the more positive results from the trials where 
only published data were available will not have greatly altered the results and their 
interpretation. Further, there was no clear evidence of a difference in the results between 
the trials with IPD and published data (P=0·07 for EFS; P=0·6 for OS). 
 
This meta-analysis of trials of adjuvant IFN-α for high-risk melanoma provides clear 
statistical evidence of benefit on EFS and, to a lesser extent, on OS, but the absolute 
differences are relatively small. The finding that ulceration may be predictive of response 
to IFN-α is an important finding, and needs confirmation in prospective studies, such as 
the EORTC 18081 trial in stage II melanoma. 
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Table 1: Trial Design and Number of Patients Randomised into Trials of Adjuvant Interferon-α Therapy versus Control for High-Risk Melanoma 
Trial Comparison Dose Schedule Duration of 
Treatment 
Total 
Planned 
Dose (MU) 
Number of 
Patients 
Randomised 
Number of 
Patients 
Analysed 
Median Duration 
of Follow-Up 
(Range) 
Trials of IFN vs. No IFN       
ECOG 
1684 
High Dose IFNα-2b 
versus Observation 
20 MU/m2/d IV 5 days per week for 4 weeks. 
Then 3 times weekly at 10 MU/m2/d SC for 48 
weeks. 
1 year 3500 N = 287 
IFN = 146 
Obs = 141 
N = 287 
IFN = 146 
Obs = 141 
16.9 years in 93 
survivors 
(0 – 19.9 years) 
ECOG 
1690 
High and Low Dose 
IFNα-2b versus 
Observation 
(3 arm trial) 
High Dose: 20 MU/m2/d IV 5 days per week for 4 
weeks. Then 3 times weekly at 10 MU/m2/d SC for 
48 weeks. 
Low Dose: 3 MU/d SC 3 times week for 2 years. 
1 year 
 
 
2 years 
3500 
 
 
936 
N = 642 
High = 215 
Low = 215 
Obs = 212 
N = 642 
High = 215 
Low = 215 
Obs = 212 
10.7 years in 294 
survivors 
(0.8 – 13.9 years) 
NCCTG 
83-7052 
High Dose IFNα-2a 
versus Observation 
20 MU/m2/d IV 3 times weekly for 12 weeks. 3 months 1350 N = 264 
IFN = 132 
Obs = 132 
N = 264 
IFN = 132 
Obs = 132 
15.1 years in 98 
survivors 
(6.2 – 18.9 years) 
Sunbelt High Dose IFNα-2b 
versus Observation 
20 MU/m2/d IV 5 days per week for 4 weeks. 
Then 3 times weekly at 10 MU/m2/d SC for 48 
weeks. 
1 year 3500 N = 218 
IFN = 112 
Obs = 106 
N = 218 
IFN = 112 
Obs = 106 
64 months  
(from abstract) 
EORTC 
18952 
Intermediate Dose 
IFNα-2b versus 
IFN Arm 1: 10 MU SC 5 times weekly for 4 weeks. 
Then 10 MU SC 3 times weekly for 1 year. 
13 months 
 
1760 
 
N = 1418† 
1 year = 565 
N = 1388 
1 year = 553 
4.6 years in 707 
survivors 
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Observation 
(3 arm trial) 
IFN Arm 2: 10 MU SC 5 times weekly for 4 weeks. 
Then 5 MU SC 3 times weekly for 2 years. 
CONTINUE treatment in case of regional relapse 
until DISTANT relapse or completion of schedule. 
25 months 1760 2 years = 569 
Obs = 284 
2 years = 556 
Obs = 279 
(0.08 – 7 years) 
Nordic Intermediate Dose 
IFNα-2b versus 
Observation 
(3 arm trial) 
IFN Arm 1: 10 MU SC 5 times weekly for 4 weeks. 
Then 10 MU SC 3 times weekly for 1 year. 
IFN Arm 2: 10 MU SC 5 times weekly for 4 weeks. 
Then 10 MU SC 3 times weekly for 2 years. 
13 months 
 
25 months 
1760 
 
3320 
N = 855 
1 year = 285 
2 years = 286 
Obs = 284 
N = 855 
1 year = 285 
2 years = 286 
Obs = 284 
72.4 months 
(from paper) 
WHO 16 Low Dose IFNα-2a 
versus Observation 
3 MU SC 3 times weekly for 3 years. 3 years 1400 N = 444 
IFN = 225 
Obs = 219 
N = 444 
IFN = 225 
Obs = 219 
6.1 years in 165 
survivors 
(0 – 8.9 years) 
UKCCCR 
AIM-High 
Low Dose IFNα-2a 
versus Observation 
3 MU SC 3 times weekly for 2 years. 2 years 936 N = 674 
IFN = 338 
Obs = 336 
N = 674 
IFN = 338 
Obs = 336 
5.5 years in 287 
survivors 
(0 – 9.3 years) 
DeCOG Low Dose IFNα-2a 
versus Observation 
3 MU SC 3 times weekly for 2 years. 2 years 936 N = 296†† 
IFN = 148 
Obs = 148 
N = 293 
IFN = 146 
Obs = 147 
3.9 years in 140 
survivors 
(0.5 – 6.9 years) 
French 
CGM 
Low Dose IFNα-2a 
versus Observation 
3 MU SC 3 times weekly for 18 months. 18 months 702 N = 499††† 
IFN = 253 
Obs = 246 
N = 489 
IFN = 244 
Obs = 245 
5 years 
(from publication) 
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Austrian 
MMCG 
Low Dose IFNα-2a 
versus Observation 
3 MU SC daily for 3 weeks then 3 MU SC 3 times 
weeks for 49 weeks. 
1 year 513 N = 311 
IFN = 154 
Obs = 157 
N = 311 
IFN = 154 
Obs = 157 
Mean = 41 
months 
(from publication) 
Scottish 
MG 
Low Dose IFNα-2b 
versus Observation 
3 MU SC 3 times weekly for 6 months. 6 months 234 N = 96†††† 
IFN = 47 
Obs = 49 
N = 94 
IFN = 46 
Obs = 48 
6.5 years in 28 
survivors 
(0.5 – 9.8 years) 
EORTC 
18871 
Low Dose IFNα-2b 
versus Observation 
1 MU SC on alternate days for 1 year. 1 year 182 N = 281 
IFN = 139 
Obs = 142 
N = 281 
IFN = 139 
Obs = 142 
7.8 years in 105 
survivors 
(0 – 14 years) 
DKG 80-1 Very Low Dose IFNα-2b 
versus Observation 
1 MU SC on alternate days for 1 year. 1 year 182 N = 203 
IFN = 101 
Obs = 102 
N = 203 
IFN = 101 
Obs = 102 
7.2 years in 94 
survivors 
(0 – 13.3 years) 
Trial of PEG-IFN vs. No PEG-IFN       
EORTC 
18991 
PEG-IFN versus 
Observation 
6 μg/kg/wk SC for 8 weeks. Then 3 μg/kg/wk SC 
for 5 years. 
5 years - N = 1256 
IFN = 627 
Obs = 629 
N = 1256 
IFN = 627 
Obs = 629 
7.54 years in 588 
survivors 
(0.3 – 10.3 years) 
Vaccine Trials       
ECOG 
2696 
High Dose IFNα-2b and 
GM2-KLH/QS-21 
vaccine (IFN either 
20 MU/m2/d IV 5 days per week for 4 weeks. 
Then 3 times weekly at 10 MU/m2/d SC for 48 
weeks. 
1 year 3500 N = 107 
IFN = 72 
Obs = 35 
N = 107 
IFN = 72 
Obs = 35 
7.1 years in 55 
survivors 
(1.4 – 8.1 years) 
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started on same day as 
vaccine or deferred until 
day 28) versus GM2-
KLH/QS-21 
ECOG 
1694 
High Dose IFNα-2b 
versus GMK vaccine 
IFN: 20 MU/m2/d IV 5 days per week for 4 weeks. 
Then 3 times weekly at 10 MU/m2/d SC for 48 
weeks. 
GMK vaccine: 1 mL of GMK vaccine administered 
via a deep SC injection on days 1, 8, 15, and 22, 
then every 12 weeks (weeks 12 to 96). 
1 year 
 
 
2 years 
3500 N = 880 
IFN = 440 
GMK = 440 
N = 880 
IFN = 440 
GMK = 440 
5.9 years in 472 
survivors 
(0 – 8.5 years) 
 
 
† In the EORTC 18952 trial, 1418 patients were randomised, but 30 patients (all from one centre) were excluded because of concerns about data quality. 
†† In the DeCOG trial, 3 patients were excluded from the intention to treat analysis due to having stage IV melanoma (n=2) or another type of malignancy (n=1). 
††† In the French CGM trial, 10 patients were excluded from the intention to treat analysis due to being ineligible (n=5) or immediate withdrawal of consent (n=5). 
†††† In the Scottish MG trial, 2 patients were excluded from the intention to treat analysis due to being ineligible (n=1) or lost to follow (n=1). 
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